Revivo Therapeutics has secured initial investments from private investors. According to Mr. Robert Bender, Chairman of the Board of Revivo Therapeutics, these investments are sufficient to advance the preclinical program substantially and position the company for support of the few IND-enabling studies to enable continuation of development. “According to Dr. Vince Kalish, SVP Chemistry, the company has selected its CMC providers and is advancing the program toward development of oral sustained release products.” Dr. Craig Hartman VP of Preclinical Development indicated that the “development plan leading to the re-submission of an IND for RIV-1061 is aggressive, but attainable within the scope of anticipated funding.”
Revivo Therapeutics announced that, following initial meetings with the North Carolina Biotechnology Council, it was applying for Company Inception Funding from NC Bio. NC Bio provides funding to enable development of promising new companies.